Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Cancer, Cancer (Solid Tumors)
Interventions: JMT108; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia

Conditions: Carcinoid
Interventions: [18F]-DOPA; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heavy Menstrual Bleeding
Interventions: Sparrow Link, Sparrow Link (Sham); Device
Lead sponsor: Spark Biomedical, Inc.; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Renal Cell
Interventions: Orellanine; Drug
Lead sponsor: Oncorena AB; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 3 more

Conditions: Alcohol Use Disorder, Alcohol Abuse, Alcoholism, Drinking Behavior, Drinking Problem
Interventions: Active Transcranial Magnetic Simulation, Sham; Device
Lead sponsor: VA Palo Alto Health Care System; Federal
Eligibility: 25 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab; Biological · Procedure · Other + 1 more
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Communication Disorder, Childhood, Autism
Interventions: Project ImPACT Training As Usual, Project ImPACT Training Plus Co-Production, Routine Project ImPACT; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Etentamig, Iberdomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 7
States / cities: Beverly Hills, California • Denver, Colorado • St Louis, Missouri + 4 more

Conditions: Sleep
Interventions: Ultradian sleep/wake protocol; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alagille Syndrome
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Kansas City, Missouri + 6 more

Conditions: Advanced Solid Tumor
Interventions: ONC-783; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Tucson, Arizona • Fountain Valley, California • La Mesa, California + 13 more

Conditions: Attention Deficit Hyperactivity Disorder Combined
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Donald Gilbert, MD, MS, FAAN, FAAP; Other
Eligibility: 8 Years to 12 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Screening
Interventions: $5 gift card, $100 monthly drawing; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Oakland, California • San Francisco, California

Conditions: Food Allergy in Children
Interventions: Food Allergy Mastery Program; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 10 Years to 14 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atopic Dermatitis, Eczema
Interventions: Tralokinumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2043
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: skin punch biopsy; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 55
States / cities: Mesa, Arizona • Sun City, Arizona • Campbell, California + 51 more

Conditions: Multiple System Atrophy, Parkinsons Disease
Interventions: Sural Nerve Graft to the Substantia Nigra, Sham surgery; Procedure
Lead sponsor: Craig van Horne, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Carcinoma, Breast Ductal Carcinoma in Situ
Interventions: Patient Navigation, Questionnaire; Behavioral · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Spinal Cord Injury, Chronic Pain
Interventions: VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

Natural History of Familial Carcinoid Tumor

Delivering tAN to Reduce HMB: The LUNA Study

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

PET/MR for Characterization of Renal Masses (RMs)

Evaluating Georgia Part C Implementation Outcomes

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Circadian Rhythms and Homeostatic Sleep Drive and Their Effect on Reward and Cognitive Control Systems in Adolescents

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Glaucoma Screening to Enhance At-Risk Californians' Health - Survey Response Incentives

Evaluation of The Food Allergy Mastery Program

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

VR Mindfulness Training for Veterans With SCI